Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19.
Shebley M, Wang S, Ali I, Krishnan P, Tripathi R, Reardon JM, Cafardi J, Rahav G, Caraco Y, Slim J, Al Akhrass F, Yu M, Hu Y, Ferreira RA, Alami NN.
Shebley M, et al. Among authors: reardon jm.
Pharmacol Res Perspect. 2023 Feb;11(1):e01036. doi: 10.1002/prp2.1036.
Pharmacol Res Perspect. 2023.
PMID: 36537346
Free PMC article.
Clinical Trial.